Apr 5, 2021 12:23pm
Chime Biologics second biologics site, pictured above, will lift total manufacturing capacity to 140,000 liters, the CDMO said.(PR Newswire/Chime Biologics)
After locking up a $125 million Series A in early 2020, China-based CDMO Chime Biologics has raised another $65 million to help build and kit out a second plant in Wuhan, China.
The $190 million investment will fuel an expansion over the next five years at its site in Wuhan, taking capacity there to 140,000 liters.
The new plant will join Chime s first facility there, which is built around a modular manufacturing system from Cytiva Life Sciences. Chime counts monoclonal and bispecific antibodies, fusion and conjugated proteins, and enzymes among its manufacturing repertoire, according to the company’s website.
Cytiva et Longitude (une entreprise du Financial Times) révèlent cinq grands défis auxquels est confrontée l industrie biopharmaceutique dans le nouveau Global Biopharma Resilience Index
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Cytiva et Longitude (une entreprise du Financial Times) révélent cinq grands défis auxquels est confrontée l industrie biopharmaceutique dans le nouveau Global Biopharma Resilience Index
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
09 marzo 2021 08:17
Fonte: Adnkronos
#salute-e-benessere
- - A survey of 1,165 biopharma executives and healthcare policymakers across 20 countries measured ability of industry to respond to global needs in five areas: Supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, and government policy and regulation
- There is a strong correlation between higher performing countries and higher income per capita; United States leads the index overall but Switzerland and China have most resilient supply chains
- First such study to cover wide range of topics and respondents
AMERSHAM, United Kingdom, March 9, 2021 /PRNewswire/ Global life sciences leader Cytiva, along with the Financial Times research arm Longitude, have compiled a global index, ranking the ability of the biopharma industry to respond to five major challenges; in supply chain, talent, research and development, manufacturing, and government policy and regulation.